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Abstract
Background
Multiple Sclerosis is more common in women than men and females have more relapses
than men. In a large international cohort we have evaluated the effect of gender on disability
accumulation and disease progression to determine if male MS patients have a worse clini-
cal outcome than females.
Methods
Using the MSBase Registry, data from 15,826 MS patients from 25 countries was analysed.
Changes in the severity of MS (EDSS) were compared between sexes using a repeated
measures analysis in generalised linear mixed models. Kaplan-Meier analysis was used to
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test for sex difference in the time to reach EDSS milestones 3 and 6 and the secondary pro-
gressive MS.
Results
In relapse onset MS patients (n = 14,453), males progressed significantly faster in their
EDSS than females (0.133 vs 0.112 per year, P<0.001,). Females had a reduced risk of
secondary progressive MS (HR (95% CI) = 0.77 (0.67 to 0.90) P = 0.001). In primary pro-
gressive MS (n = 1,373), there was a significant increase in EDSS over time in males and fe-
males (P<0.001) but there was no significant sex effect on the annualized rate of EDSS
change.
Conclusion
Among registrants of MSBase, male relapse-onset patients accumulate disability faster
than female patients. In contrast, the rate of disability accumulation between male and fe-
male patients with primary progressive MS is similar.
Introduction
In multiple sclerosis (MS), the female to male ratio is as high as 3:1 [1,2]. However, while men
have a lower risk of developing MS, many natural history and patient cohort studies have sug-
gested that male sex is associated with a poorer clinical outcome in relapse-onset cohorts
(RRMS, SPMS). In this form of MS, representing up to 85% of all MS cases, male patients are
reported to have a more rapid accumulation of disability [3,4,5,6], reach disability milestones
more rapidly than their female counterparts [7,8,9,10,11], display a more malignant form of
disease [12] and have a poorer recovery after the initial disease relapse than females [13].
The rate at which patients reach the secondary progressive disease course (SPMS) is also po-
tentially impacted by sex. Male sex has been associated with a faster time to progressive MS in
some studies [7,14] but not others [15,16].
Primary progressive MS (PPMS) is a clinically distinct form of MS in which the accumula-
tion of disability occurs in the absence of clinical relapses and patients experience a progressive
course from disease onset [17,18]. PPMS patients are older at disease onset [19] than RRMS pa-
tients and there the sex ratio is 1:1 [20]. Male PPMS patients have been shown to accumulate
disability more rapidly than their female counterparts even in the early stages of the disease [8].
Although no predictive effect of sex on the time to reach EDSS 6 has been seen [21, 22], sex has
been shown to have prognostic value when it comes to disease progression to higher levels of
disability with faster rates of reaching EDSS levels of 8 [23] and 10 [24] observed in male PPMS
patients. In a multicentre prospective study of prognostic factors in PPMS, conducted across 5
European countries [25], male PPMS patients were also shown to be twice as likely to deterio-
rate than female patients over 10 years of follow up.
In the current study, we have used longitudinal clinical outcome data, extracted from a large
international, multicentre database, the MSBase Registry [26], to assess if sex affects the accu-
mulation of disability in relapsing remitting MS, progression to the secondary progressive
phase and disease progression in the primary progressive MS phenotype.
Male MS Patients Fare Worse
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Methods
The MSBase Registry
The MSBase Registry was established in 2006[26] and is a prospective, international, web-
based database collecting standardized clinical outcomes in MS patients using an agreed mini-
mum dataset. The Registry collects clinic-based and private practice based information on peo-
ple with MS. From its inception in 2006, data was prospectively collected from patients and
entered on to the Registry together with retrospective data derived from the patient’s medical
history thereby enabling long term clinical follow up. Patient information is recorded at each
of the collaborating centers using the offline medical record iMED and then uploaded to the
MSBase web portal. The use of MSBase as a research platform was approved by the Melbourne
Health Human Research Ethics Committee and by the local human research ethics committee
at all participating centers, or in some cases relevant exemptions were granted, in accordance
with local laws and regulations. Signed informed consent was obtained from each participating
patient if required.
Quality assurance of clinical data was maintained by inbuilt data quality checking in the
iMED local record system and data quality reporting fromMSBase. To ensure consistency of
EDSS evaluations all neurologists completed the Neurostatus certification (Kappos L, http://
www.neurostatus.net) or provided evidence of prior completion of this certification.
Statistical Methods
Change in EDSS over time. The analysis of change in scores on the EDSS was done sepa-
rately for those with PPMS and for the combined group of patients with SPMS or RRMS.
In each cohort outcome measurements included evaluations of the impact of sex on disabili-
ty accumulation by evaluating the effect on annualized EDSS change.
All statistical analyses were performed using SAS 9.3 statistical software program (SAS Insti-
tute, Cary, NC, USA).
A repeated measures analysis, using data from all EDSS time points, after initial EDSS, re-
corded at the first visit recorded to the MSBase Registry, was conducted using generalised linear
mixed models. The outcome in the model was the subjects’ EDSS. The main independent vari-
ables were sex, years since onset of MS and the interaction term of sex by years since disease
onset. The p-value from the interaction term was used to determine if there was a statistically sig-
nificant difference between men and women in the change in EDSS scores over time. The time
variable in the model was calculated as date of visit (for assessment of EDSS) minus the date of
MS symptom onset. The models were adjusted for a number of potential confounding variables
including treatment (the numbers of days used prior to the last EDSS assessment), age at first
symptom and country of birth. Available treatments during the observation period of this study
included Interferon β-1a formulations, Interferon- β1b, glatiramer acetate and natalizumab.
Time to reach EDSS milestones 3 and 6. The time to reach EDSS milestones 3 or 6 were
estimated for each sex in the RR/SPMS and PPMS cohorts, used in the evaluations of the
change in EDSS over time, by Kaplan Meier Survival models. The time period to reach EDSS 3
or 6 was evaluated from the time of onset of symptoms to the time of the first clinic visit re-
corded to the Registry at which the EDSS was above the cut point of EDSS 3 or EDSS 6. The
statistical models used assumed that all patients used in the analysis had an EDSS less than 3 or
6 at the time of onset of symptoms, however, the EDSS milestones may have been reached at
the first clinic visit entered to the Registry.
Time to progression to SPMS. The time of SPMS disease course conversion from RRMS
was derived from the time of onset of symptoms to the onset of SPMS diagnosis provided by
Male MS Patients Fare Worse
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the participating neurologist at each participating centre. The diagnosis of SPMS was per-
formed according to the international accepted definition of demonstrated disease progression
independent of relapses for at least 6 months in patients previously classified as RRMS [27]. A
Cox Proportional Hazards model was used to examine time from onset of symptoms to diag-
nosis of SPMS among patients. This model was also adjusted for treatment, age at first symp-
tom and country of birth.
Results
MS patients were enrolled to the MSBase Registry if their clinic data met the minimum dataset
requirements for eligibility which included the collection of mandatory patient profile data at
the entry visit, and at least an annual follow-up visit. Key data collected from each visit includ-
ed relapse rate, relapse treatment, MS specific therapies used, EDSS and diagnostic tests per-
formed [26]. On February 6 2012, data was extracted from the MSBase Registry for 18,885 MS
patients who fulfilled MSBase Registry minimum dataset requirements. Data was derived from
55 collaborating centers in 25 countries. Patients were considered evaluable in assessments of
the change in disability accumulation over time, in the current study, if there was a recorded
date for the confirmed diagnosis of MS and of their MS course designation as being either
RRMS, SPMS or PPMS. Dates were also required for the visit dates during which their EDSS
scores were assessed. When applying these criteria, for evaluable data required for this study,
we derived data for 14,453 MS patients, with a diagnosis of RRMS or SPMS, and 1373 patients
with a diagnosis of PPMS. Patients were considered evaluable for Kaplan Meier analysis, of the
time to developing SPMS, if there was a recorded date for the onset of disease symptoms and
they were not progressive from onset. When applying these criteria we derived data from
16,487 MS patients for survival curve analysis.
The sex distribution in combined RR/SPMS patient group showed a female to male ratio of
2.5:1. Demographic features of each sex were comparable at the initial onset of MS, however
statistically, males were significantly older than females and their initial EDSS was higher than
that of their female counterparts (Table 1). The time period between their initial onset of symp-
toms to their most recent visit date for both males and female patients was comparable, with a
median of 9.9 years (min 2 days, max 34.96 years) for males and a median of 10.4 years (min 1
day, max 34.99 years) for females. 70% of of all patients were exposed to disease modifying
therapies, during the observational period and this occurred to the same extent in both male
and female populations.
Unlike the marked female sex bias noted in the RR/SP MS group, the primary progressive
group reflected a more even distribution between sexes, with a female to male ratio of 1.2:1
(Table 1). Diagnosis of primary progressive MS occurred in an older patient population with
Table 1. Demographics of patients with relapsing- remitting (RR) / secondary progressive (SP) and
primary progressive (PP) MS at the initial visit recorded to the MSBase Registry.
Variable Males Females p-value
RR/SP MS Number 4051 10304
Age at onset (years) 30.5 (9.8) 30.0 (9.8) 0.011
Initial EDSS 2.8 (1.9) 2.6 (1.9) 0.001
PP MS Number 619 747
Age at onset (years) 39.7 (10.6) 40.1 (11.0) 0.517
Initial EDSS 4.6 (5.1) 5.1 (5.5) 0.318
Data are shown as mean (+/- SD)
doi:10.1371/journal.pone.0122686.t001
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the age at disease onset being approximately 10 years later than that seen in the RR/SPMS
group (Table 1). The mean level of disability recorded at the initial visit entered on the Registry
was higher in the PPMS group (EDSS 4.7 ± 1.9) compared to that seen in RR/SP MS patients
(EDSS 2.8±1.9) and was comparable between sexes (Table 1).
In the RR/SPMS patient group the effect of sex on the rate of change in disability up to a max-
imum of 35 years from the initial onset of symptoms to the most recent recorded visit date was
evaluated (Fig 1). Table 2 shows the number of patients contributing to this evaluation at 5 year
intervals between visits. There was a statistically significant increase of 0.124 (0.119 to 0.129)
units per year in the mean level of EDSS scores over time for men (P<0.001) and 0.107 (0.104 to
0.111) for women (P<0.001). The increase in the mean level of EDSS differed significantly be-
tween sexes (P<0.001) with the disability increasing slightly faster in males than females (Fig 1).
Fig 1. Mean value of EDSS for men and women with secondary progressive or relapsing remitting MS
by number of years since initial EDSS. EDSS is shown as mean value ± SD. Disease duration was derived
as the date of the visit at which the EDSS was determined minus the date of onset of MS symptoms. Red
squares = females, blue circles = males.
doi:10.1371/journal.pone.0122686.g001
Table 2. Number of male and female RRMS/SPMS patients who provided at least one valid EDSSmea-
surement in each 5 year period.
Years since initial symptoms Male Female Total
<4 2302 5561 7863
5 to 9 1951 4953 6904
10 to 14 1433 3696 5129
15 to 19 859 2301 3160
20 to 24 540 1408 1948
25 to 29 307 810 1117
30 to 34 151 479 630
doi:10.1371/journal.pone.0122686.t002
Male MS Patients Fare Worse
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The number of valid EDSS measurements per person contributing to this evaluation was compa-
rable between males (median 5, min 1, max 68) and females (median 6, min 1, max 73).
The time to reach disability milestones 3 and 6 was evaluated in 14,355 RR/SPMS patients.
On average it took 8 years after the initial onset of symptoms for the male RR/SP MS popula-
tion to reach EDSS 3 while it took 10 years for the female population to reach this level. At the
higher level of disability in the male population, EDSS of 6 was reached at 32 years after the ini-
tial visit, whilst the mean for the female population did not reach this level of disability within
the observed time frame (Fig 1).
In the PPMS population, there was a statistically significant increase in EDSS scores over
time for men (P<0.001) and for women (P<0.001) up to 35 years following the initial onset of
symptoms, but unlike the sex differences seen in the RR/SP group, there was no significant dif-
ference in the annualized change in EDSS between sexes in PPMS (P = 0.889) (Fig 2). Table 3
Fig 2. Mean value of EDSS for men and women with primary progressive MS by number of years
since initial EDSS. EDSS is shown as mean value ± SD. Disease duration was derived as the date of the
visit at which the EDSS was determined minus the date of onset of MS symptoms. Red squares = females,
blue circles = males.
doi:10.1371/journal.pone.0122686.g002
Table 3. Number of males and female PPMS patients who provided at least one valid EDSSmeasure-
ment in each 5 year period.
Years since initial symptoms Male Female Total
<4 268 312 580
5 to 9 301 374 675
10 to 14 211 283 494
15 to 19 132 192 324
20 to 24 84 103 187
25 to 29 49 56 105
30 to 34 28 33 61
doi:10.1371/journal.pone.0122686.t003
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shows the number of patients contributing to this evaluation at 5 year intervals between visits.
The median duration between the initial onset of symptoms and the most recent visit date re-
corded to the Registry was comparable between males (median 10.57 years, min 0.23 years,
max 34.88 years) and females (median 11.28 years, min 0.42 years, max 34.90 years). The num-
ber of valid EDSS measurements per person contributing to this evaluation was comparable be-
tween males (median 4, min 1, max 63) and females (median 4, min 1, max 60).
The EDSS level at onset of symptoms in the PPMS group (n = 1366) was higher than that
seen in the RRMS group (Table 1) and the increase in disability was faster: it took approximate-
ly 15 years after the onset of symptoms to reach a mean EDSS 6 (Fig 2).
Disease progression rate was evaluated from the onset of symptoms to the time to reach
SPMS using Kaplan-Meier survival analysis (Fig 3). A diagnosis of SPMS was recorded in 2,664
MS patients. The derived median time to reach secondary progressive MS was 25.1 years for
men and 29.5 years for women. Survival analysis, using Cox Proportional Hazards models, sug-
gest that women had a statistically significant reduced risk of developing SPMS compared to
men [HR (95% CI) = 0.77 (0.67 to 0.90); P = 0.001], indicating that in this multinational MS
cohort study, male RRMS patients reach the progressive phase earlier than females.
Discussion
In this study we evaluated the effect of sex on the rate of accumulation of disability and time to
disease progression in 15,721 MS patients with a confirmed diagnosis of multiple sclerosis.
This represents the largest study population evaluated to date and exceeds by far regional MS
natural history studies conducted in Lorraine (2,871 cases, [4,5]), Lyon (1,844 cases, [7,8]), and
Rennes, France (2,054 cases, [10]), or London Ontario (1,099 cases [28]) and British Columbia,
Fig 3. Kaplan-Meier estimates of time to secondary progressive MS by sex.
doi:10.1371/journal.pone.0122686.g003
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PLOS ONE | DOI:10.1371/journal.pone.0122686 June 5, 2015 7 / 11
Canada (2,387 cases, [29]). Data derived from the MSBase database mirrors the sex bias to-
wards female patients in the relapsing remitting and secondary progressive MS phases reported
in other large regional epidemiological studies [2,3,4,6,7,8,10,13]. The rate of disease progres-
sion we observed is also comparable to that seen in regional cohort studies with the time taken
to reach early disability milestone of EDSS 3 being similar to that seen in Rennes, France (10
years, n = 1609) [10], and London Ontario, Canada (8 years, n = 2236) [28]. With respect to
reaching a higher level of disability (EDSS 6) our male cohort reached this level 32 years follow-
ing their initial recorded EDSS while our female cohort did not reach this level of disability
within the maximum observation period of 34 years. This represents a slower rate of progres-
sion in female patients than reported by others, with female cohorts in French databases from
Lorraine, Lyon and Rennes reaching EDSS 6 within 24 years, 23 years and 20 years, respectively
[4,7,8,10]. The most rapid rate of disability progression was reported in Canada with the total
London Ontario RRMS patient population reporting a median time to reach EDSS 6 within 15
years [28] while the Canadian British Columbia cohort displayed a far more protracted rate of
decline with a median time to EDSS 6 of 27 years [29]. There are several possible factors that
may account for the regional variations in the rate of accumulation of disability. The clinical
outcomes data we derived from the MSBase Registry was analyzed a decade after several of the
French datasets were acquired. Consequently, it is possible that the range of disease modifying
therapies recorded in the MSBase Registry reflects current clinical practices they may be im-
pacting on clinical outcomes which is in contrast to earlier studies performed at a time of a
much more limited treatment armory [7,8]. This may also be contributing to a shift in the se-
verity of cases presenting to clinics with a milder disease course that could be impacting on the
clinical outcome profile we are recording to the MSBase Registry.
In relapse-onset MS patients we have shown that male patients start off with a slightly
higher EDSS than female patients at their first clinic visit entered to the MSBase Registry and
they accumulate disability faster. This finding has been supported by others who have shown a
more rapid attainment of EDSS scores of 4, 6 and 7 from onset in male patients [3,6,8,10].
However, the effect of sex on rate of disability accumulation in relapsing remitting MS has
been challenged, with the suggestion that it is in fact a two stage process, and factors such as
sex only impacting on the attainment of disability levels up to EDSS 3 [8,10], and not on the
level of disease accumulation in the later phase, from EDSS 3 up to EDSS 6. This suggests that
the sex effect on disability change was confined to the early inflammatory disease process and
has limited influence on the later, degenerative phenotype. While we did not explore these pos-
sibilities, we do show that annualized EDSS change was faster in males across a range of EDSS
levels and a more rapid attainment of EDSS 6 was seen in male patients.
There is consensus between regional cohort studies regarding the time taken for relapsing
remitting patients to reach the secondary progressive disease phase with most studies reporting
a 20 year duration from disease onset to onset of secondary progressive MS [4,30,31]. A com-
parable time course for the development of progressive disease has also been reported by others
in their female populations exclusively [4,14,31]. In contrast, the median time to reach this
phase was delayed in our MSBase patient population up to 29.5 years for female patients. Our
findings increase the weight of evidence for a significant sex effect on the time to SPMS and
supports other regional studies that that show a more rapid rate of progression in males
[4,9,14]. The exception being a study from Groningen, Netherlands [16] that was unable to
demonstrate any impact of sex on disease progression.
One potential limitation of the current study was that the diagnostic criteria for reaching
the secondary progressive phase was not dictated by MSBase, but rather determined by the
treating neurologists at each participating site and the usage of the appropriate definition of
SPMS was not audited. However, the international accepted definition was known to be
Male MS Patients Fare Worse
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implemented in clinical practice by a large number of MSBase investigators and it is unlikely
that the criteria used differed between males and females and therefore do not explain our gen-
der difference. It has also been suggested [32] that the clinical designation of SPMS is more ac-
curate than deriving the time for reaching the progressive phase by applying an algorithm to
clinical outcome data.
Baseline demographic data, derived from the first clinic visit entered to the Registry, in the
current study also indicated that males were marginally but significantly older (mean 0.5 years)
at relapsing remitting MS onset. Indeed the age at onset of symptoms has been proposed as a
major prognostic factor of progression of disease, with an older age at disease onset associated
with a poorer disease outcome [1,13], and a more rapid development of the progressive phase
of the disease [15,16,33]. However, we still found faster disability progression in males after ad-
justing for age of onset differences.
Another potential variable that could impact on disease severity and progression in relapse
remitting MS is relapse rate. It is, however, unlikely that the sex effects seen in our study are ex-
plained by relapse rate as recent evaluation of relapse incidence, utilizing clinical outcomes
from the same MSBase registry [34], indicates that relapse frequency was higher in females
compared to males, at all relapsing-onset disease stages. This suggests that other factors are
contributing to the poorer clinical outcomes we are observing in male patients. Indeed, it has
been suggested that factors other than relapse rate impact on long term disability in MS, evi-
denced by a lack of effect of relapse rate on long term disability accumulation or the time to
reach the secondary progressive phase of MS [35,36].
Primary progressive MS is clinically distinct from relapsing-onset MS as it is believed to be
associated with a prominent degenerative pathology from disease onset [17,20,27]. We evaluat-
ed clinical outcomes of 1336 primary progressive patients representing the largest clinical anal-
ysis of primary progressive MS conducted to date. The later age at onset of primary progressive
MS patients and sex parity observed in our study population is comparable to that seen in re-
gional cohort studies of primary progressive MS [20,21,23,28,35,37]. The time taken to reach
EDSS 6 was almost halved compared to patients with relapsing remitting disease, suggesting a
significantly poorer prognosis and more rapid rate of disability accumulation in this form of
MS. The median time for primary progressive MS patients to reach the EDSS 6 milestone in
the MSBase study population (15 years) is comparable to that seen in the British Columbia da-
tabase (14 years, n = 552 [21]), but is more protracted than that reported in Wales (9.6 years,
n = 234 [23], London Ontario (8.5 years, n = 216 [37]) and in Lyon (7.1 years, n = 282 [8]).
In the MSBase population there was no evidence of an effect of sex on the rate of accumula-
tion of disability over time in primary progressive patients. There is an apparent lack of con-
sensus on the prognostic value of sex on disease progression in primary progressive MS, which
may in part be due to differences in the stages of disability accumulation and outcomes being
evaluated. Male sex has been associated with a faster time to reaching EDSS milestones 4, 6 and
7 in the Lyon population [8], but not in the London Ontario group, where sex failed to impact
on time to earlier EDSS milestones but EDSS 10 (death) was reached faster by male patients
[37]. In a 10 year follow up study of 145 PPMS patients across 5 European centers, males with
PPMS had worse outcomes [25]. However, our much larger study refutes this, finding no sex-
associated difference in PPMS progression rates.
Conclusions
We have shown that male MS patients with relapse-onset have more rapid annualized EDSS
progression, shorter time to SPMS, and shorter time to EDSS milestones 3 and 6. On the other
hand, in our large cohort of primary progressive MS patients, we found no sex-associated
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effects on rate of disability accumulation. Overall, our large cohort study showed a slower dis-
ease progression than previous studies, likely due to greater uptake of disease modifying drug
treatment and the advent of more effective drugs in our cohort, although an increased ascer-
tainment of milder MS cases could also contribute.
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